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Human interleukin-4 possesses two distinct sites for receptor activation. A signaHing site, com-
prising residues near the C-terminus on helix D, determines the efficacy of interleukin-4 signal 
transduction without affecting the binding to the interleukin-4 receptor a subunit. A complete 
antagonist and a series of low-efficacy agonist variants of human interleukin-4 could be generated 
by introducing combinations of two or three negatively charged aspartic acid residues in this site at 
positions 121, 124, and 125. One of the double variants, designated [R121D,Y124D]interleukin-4, 
with replacements of böth Arg121 and Tyr124 by aspartic acid residues was completely inactive in 
all analysed cellular responses. The loss of efficacy in [R121D,Y124D]interleukin-4 is estimated to 
be !arger than 2000-fold. Variant [R121D,Y124D]interleukin-4 was also a perfect antagonist for 
inhibition of interleukin-13-dependent responses in B-cells and the TF-1 cellline with a Kj value of 
approximately 100 pM. In addition, inhibition of both interleukin-4-induced and interleuk.in-13-
induced responses could be obtained by monoclonal antibody X2/45 raised against interleukin-4Rm 
the extracellular domain of the interleuk.in-4 receptor a subunit. These results indicate that efficient 
interleukin-4 antagonists can be designed on the basis of a sequential two-step activation model. In 
addition, the experiments indicate the functional participation of the interleukin-4 receptor a subunit 
in the interleukin-13 receptor system. 
Human interleukin-4 (IL-4) activates its cognate receptor 
system by sequential binding to two different receptor sub-
units. The frrst high-affinity binding step (Kd 100 pM) in-
volves the interaction between IL-4 receptor a subunit (Beck-
mann et al., 1992 ; Galizzi et al., 1990; Idzerda et al., 1990) 
and IL-4 amino acid residues located on helices A and C 
(Kruse et al., 1993; Ramanathan et al., 1993). The subse-
quent second binding step involves a signalling site on helix 
D of IL-4 (Kruse et al., 1992) and a further receptor subunit, 
which according to recent evidence (Kondo et al., 1993; Rus-
sell et al., 1993) is probably the y chain of the IL-2 receptor 
system, now designated 'Yc· 
Such a sequential two-step binding mechanism leading 
to receptor activation suggests a rationale for the design of 
antagonistic cytokine variants (Cunningham et al., 1991 ; De 
Vos et aJ., 1992). If the first high-affinity binding site is re-
tained and the second signalling site is either destroyed by 
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Abbreviations. IL-4, interleuk.in-4; IL-13, interleuk.in-13; EC5o, 
effector concentration resulting in half-maximal response; Rmu ... , 
maximal response obtained at saturation levels; IC50, concentration 
resulting in half-maximal inhibition; IL-4R .... soluble IL-4 receptor; 
[R 121 D, Y124D]IL-4, [R 121 D,S 125D]IL-4, [Y124D,S 125D] IL-4 
and [R121D,Y124D,S125D]IL-4, variants of IL-4 where combina-
tions of Arg121, TYr124 or Ser125 have been replaced by aspartic 
acid. 
mutations (Fuh et al., 1992; Kruse et al., 1992) or blocked 
by monoclonal antibodies (Reusch et al., 1994), the oligo-
merisation process stops at the Ievel of the unproductive 1 : 1 
complex between the cytokine and the first receptor subunit. 
The signalling site of human IL-4 comprises side chains of 
Arg121, Tyr124 and Ser125. Previous results have shown 
that variants [R121D1IL-4 and [S125D1IL-4 have approxi-
mately 30% partial agonist activity and variant [Y124D]IL-
4 has less than 1% partial agonist activity for T-cell prolifera-
tion compared to wild-type IL-4. High-affinity binding to the 
IL-4 receptor a subunit is retained in these variants as shown 
by in vitro binding experiments (Kruse et al., 1992). Accord-
ing to high-resolution three-dimensional NMR spectroscopy 
(Müller et al., 1994; Müller, T., unpublished results) the con-
formational changes produced by replacement of IL-4 
Tyr124 by glycine or aspartic acid are confined to the imme-
diate environment of the side chain. No changes in the sec-
ondary or tertiary structures of these IL-4 variants compared 
to the wild-type protein could be detected. 
The variant [Y124D]IL-4 behaves as a complete antago-
nist for IL-4-dependent T-cell proliferation in vitro. It has, 
however, a partial agonist activity of up to 40% for the in-
duction of CD23 expression in B-cells. The reason for this 
difference is not clear. Therefore, it was investigated as to 
how far this residual partial agonist activity on B-cells can 
be abolished by introducing combinations of two or three 
aspartic acid residues at positions 121, 124 and 125. More 
than additive effects could be observed if double-mutant and 
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triple-mutant proteins were analysed for partial agonist and 
antagonist activity in B-cells and T-cells. One of the double 
variants, [R121D,Y124D]IL-4, behaved as a complete 
antagonist during all analysed cellular responses. 
Remarkably, not only IL-4-dependent but also IL-13-de-
pendent B-ce11 responses were completely antagonized by the 
novel IL-4 variant [R121D,Y124D]IL-4. Similar results have 
recently been reported for variant [Y124D]IL-4 (Aversa et 
al., 1993; Zurawski et al., 1993). Furthermore, a monoclonal 
antibody XZ/45 raised against the recombinant extracellular 
domajn of the IL-4 receptor was also found to inhibit both 
IL-4-dependent and IL-13-dependent B-cell responses. These 
results provide independent conclusive evidence that the 
cloned IL-4 receptor a. subunit is an essential constituent of 
the IL-13 receptor system. 
MATERIALS AND METHODS 
Recombinant human IL-13, produced and purified from 
Escherichia coli, was from IC Chemikalien GmbH. 
Human IL-4 variants were generated by in vitro mutagen-
esis, expressed in E. coli, renatured and purified (Kruse et al., 
1991, 1992). Variants were designated [R121D,Y124D]IL-4, 
[Y124D,S125D]IL-4, [R121D,S125D]IL-4, and [R121D, 
Y124D,S125D]IL-4, indicating the replacement of Arg121, 
Tyr124, or Ser125 by aspartic acid. 
Monoclonal antibodies to IL-4Rex, the extracellular do-
main of the IL-4 receptor a. chain, were generated by stan-
dard procedures using recombinant human IL-4Rex produced 
in Chinese hamster ovary cells as antigen (Kruse et al., 
1993). 
Assays for competition with radioligand binding, human 
T-cell proliferation, and induction in B-cells of CD23 (Fes 
RU), the low-affinity receptor for lgE, have been described 
(Kruse et al., 1992; Kruse et al., 1993). 
Statistical evaluations 
All measurements were evaluated by means of the GraFit 
program (Erithacus Software) using the equation y = a/ 
(1 +[X//]expS) + back (IC50-4 parameter logistic). 
RESULTS 
Binding properties of double 
and triple IL-4 mutant proteins 
In previous experiments (Kruse et al., 1992), the variants 
[R121D]IL-4, [Y124D]IL-4 and [S125D]IL-4 were shown to 
retain high-affinity binding to the IL-4 receptor a. chain. Ta-
b1e 1 shows that the occurrence of two or three negatively 
charged residues in the double and triple variants does not 
significantly alter the binding to the recombinant extracellu-
lar domain of the IL-4 receptor a subunit (IL-4Rex). The Kd 
values are in the range 50-300 pM. These values are similar 
to those displayed by the single mutants (Kruse et al., 1993). 
These findings are consistent with recent structural data 
(Müller et al., 1994) showing that the conformation of the 
IL-4 protein is not altered by the amino acid replacement 
causing only local perturbations at the site of the changed 
side chain. Thus, it is reasonable to conclude that for the 
vru.iants with multiple changes described in this study, the 
secondary and tertiary structures also remain grossly unal-
tered. 
Table 1. Dissociation constants Kd between IL-4Re" and IL-4 
variants [R121D,Y124D]IL-4, [R121D,S12SD]IL-4, [Y124D, 
S12SD]IL-4 and [121D,Y124D,Sl25D]IL-4. The Kd values were 
detennined by means of competitive radioligand binding to IL-4Rex 
between 1251-labeled IL-4 and unlabeled IL-4 or variants (Kruse et 
al., 1992). The concentration of 1251-labeled IL-4 was 0.59 nM in 
experiment 1 and 0.32 nM in experiment 2. The Kd value for IL-4 
of 100 pM was determined from the dose-dependence of receptor 
saturation after correcting for unspecific binding (Kruse et al., 1993). 
The Ku values represent mean values ::t the standard deviation. 
Protein 
IL-4 
[Rl21D,Y124D]IL-4 
[R121D,Sl25D]IL-4 
[Y124D,S125D]IL-4 
[R121D,Y124D,S125D]IL-4 
Dissociation constant Kd 
experiment 1 
pM 
100:!: 17 
105 ± 14 
50± 5 
170±20 
180 :± 30 
experiment 2 
100 ± 18 
90:± 13 
90± 3 
95 ± 12 
200± 35 
Biological activities of variants as determined 
by T-cell proliferation 
All variants in Table 2 failed to stimulate T-cell prolifera-
tion significantly above background Ievels. Residual activi-
ties with mean values of 0-1.3% of wild-type IL-4 maximal 
response (Rmax) were obtained with standard deviations in the 
same range or even larger. Thus, the loss of efficacy for this 
T-cell response is at least 100-fold. These results might have 
been anticipated for variants [R121D,Y124D]IL-4, [Y124D, 
S125D]IL-4, and [R121D,Y124D,S125D]IL-4 all containing 
the replacement of Tyr124 with aspartic acid, since the 
[Y124D]IL-4 variant does not stimulate T-cell proliferation. 
The loss of efficacy in variant [R121D.S125D]IL-4, how-
ever, appears to be more pronounced than expected from an 
additive effect of the single amino acid replacements in vari-
ants [R121D]IL-4 and [S125D]IL-4 both of which retained 
20-40% partial agonist activity (Kruse et al., 1993). 
All variants inhibit IL-4-dependent T-cell proliferation 
with Ki values of 460-750 pM. The range of these Kj values 
is 3-6 fold higher than the EC50 value of IL-4 (Fig. 1, Table 
2). 
Partial agonist/antagonist activity of variants 
during CD23 induction in B-cells 
The induction of CD23-positive B-cells requires much 
lower IL-4 concentrations (EC50 values of 1-3 pM) com-
pared to the stimulation of T-cell proliferation. The CD23 
content in the positive B-cells increases at somewhat higher 
IL-4 concentration (EC50 values 6-18 pM). As demonstrated 
in Fig. 2 and Table 3, clear partial agonist activities are ob-
served with some of the signaHing site variants in these sensi-
tive B-eeil assays. The double variant [R121D,S125D]IL-4 
produces similar maximal responses as [Y124D]IL-4, i.e. 
28% versus 29% of the maximal nurober of CD23-positive 
cells induced by IL-4, or 12% versus 8% of the maximal 
CD23 content. The Rmax values produced by variants 
[Y124D,S125D]IL-4 and [R121D,Y124D,S125D]IL-4 are 
lower than those produced by [Y124D]IL-4, but are clearly 
above the background Ievel. No significant response is ob-
served in the presence of variant [R121D,Y124D]IL-4. The 
loss of agonist activity in [R121D,Y124D]IL-4 is more than 
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Fig. 1. Inhibition of T-cell prolüeration by IL-4 variants [R121D, 
Y124D]IL-4, [R121D,Sl25D]IL-4, [Y124D,S125D]IL-4, and 
[R121D,Y124D,Sl25D]IL-4. Activated human T-cells (prestimu-
lated with phytohemagglutinin) were incubated with 2 nM IL-4 plus 
the indicated concentration of IL-4 variant [R121D,Y124D]IL-4 
(e), [R121D,S125D]IL-4 (0), [Y124D,S125D]IL-4 (A), and 
[R121D,Y124D,S125D]IL-4 (t6.) for three days before [3H]thymi-
dine incorporation during 4 h was determined. 
Table 2. Partial agonist and antagonist activities of variants 
[Rl21D, Y124D]IL-4, [R121D,S125D]IL-4, [Y124D,S125D]IL-4 
and [R121D, Y124D,S125D]IL-4 on T-cell proliferation. The in-
hibitory constant K; was calculated from IC50 values as determined 
by the experiments in Fig. 1; K; = ICso/(1 + [IL-4]/EC50). [IL-4] 
was 2 nM and the EC50 of IL-4 was 140 pM during this set of 
experiments. The Rmax. and K; values represent mean values :±: the 
standard deviation. The background measured without IL-4 was 
5.4% :±: 1.1 and was substracted from all Rmax values. 
Protein 
IL-4 
[R121D,Y124D]IL-4 
[R121D,S125D]IL-4 
[Y124D,S125D]IL-4 
[R121D,Y124D,S125D]IL-4 
Rmax for T-cell 
proliferation 
% 
100 ± 6.5 
0 ±1 
1.3 ± 1.4 
0.4 ± 0.7 
0.2± 1.2 
pM 
670 ± 15 
750:±: 80 
460± 35 
540:±:20 
20-fold compared to variant [Y124D]IL-4. Considering the 
at least 100-fold loss of agonist activity of [Y124D]IL-4 dur-
ing the T-cell proliferation response, the efficacy of variant 
[R121 D,Y124D]IL-4 appears tobe reduced more than 2000-
fold compared to IL-4. lt remains unclear why [R121D, 
Y124D,S125D]IL-4 but not variant [R121D,Y124D]IL-4 re-
tains a small residual partial agonist activity. 
Inhibition by antagonistic variants 
of IL-4-induced CD23 expression 
All double and triple variants are efficient inhibitors of 
IL-4-induced CD23 expression in B-cells (Table 4). The 
maximal Ievel of inhibition obtainable is determined by the 
specific partial agonist activity of each variant (Table 3). The 
K; values calculated from the concentrations producing 50% 
inhibition (IC50) and the actual IL-4 concentration and the 
EC50 value of IL-4 for the particular response (see Materials 
and Methods) are in the range 70-320 pM, and are, hence 
similar to the Ki value observed for [Y124D]IL-4 (Kruse et 
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Fig. 2. Partial agonist activities of IL-4 variants during induction 
of CD23 (Fee Rll) in human B-cells. Human B-cells purified from 
spieen were incubated with the indicated concentrations of IL-4 ( + ), 
or variants [Y124D]IL-4 (X), [R121D,Y124D]IL-4 (e), [R121D, 
S125D]IL-4 (0), [Y124D,S125D]IL-4 (A), and (R121D,Y124D, 
S125D]IL-4 (.6) during 18 h and were analysed for the number of 
CD23-positive cells (A) and the mean CD23 content (B). For eval-
uation see Table 3. 
al., 1992). Apparently, despite the different partial agonist 
activities of the variants, the K; values are similar. This indi-
cates that variant [R121D,Y124D]IL-4, showing the most 
pronounced acti vation deficiency, is a complete high-affinity 
antagonist. 
Inhibition of IL-13-induced CD23 expression 
CD23 can also be induced in human B-cells upon stimu-
lation with IL-13 (McKenzie et al., 1993; Minty et al., 1993; 
Punnonen et al., 1993). The maximal responses are lower, 
however, than those obtainable with IL-4 (Table 5). At Satu-
ration Ievels of IL-13, the number of CD23-positive cells is 
only approximately 67% the number of cells inducible by 
IL-4, and the mean CD23 content is approximately 33% (Ta-
ble 5). This suggests that only a subpopulation of IL-4-re-
sponsive B-cells is also responsive to IL-13, and, further-
more, that even in the IL-13-responsive subpopulation the 
IL-13-inducible CD23 content is lower (less than 50%). The 
EC50 values of IL-13 are higher than those of IL-4. In the 
experiment described in Table 5, differences between EC50 
values were more than tenfold. The variant [R121D, 
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Table 3. Partialagonist activities of IL-4 variants on CD23 induction in B-cells. A background value of 6.6% (10.1 %) CD23-positive 
cells and of 3.5% (2.9%) mean CD23 content measured without IL-4 was subtracted from all numbers in experiment 1 (experiment 2). 
The EC~o of IL-4 for induction of CD23-positive B-cells was 1 pM (3 pM) and of mean CD23 content 6 pM (18 pM) during experiment 
1 (experiment 2). The values represent mean values ::!: the standard deviation. 
Protein Maximal response Rmax for induction of 
CD23-positive B-cells mean CD23 content 
experiment 1 experiment 2 experiment 1 experiment 2 
% 
IL-4 100 ::!:2.6 100 100 ::!: 0.1 100 
fR121D,Y124D]IL-4 0.6::!: 1.5 - 2.9::!:3.2 0.7::!:0.9 - 0.4±0.5 
lR121D,S125D]IL-4 28 ::!:4.1 25 :!: 1.2 12 ::!:0.3 9.4± 1.1 
[Y124D,S125D]IL-4 9.3::!:2.6 4.3 :!:3.3 2.8:!: 1 1.1 ±0.6 
[R 121D,Y124D,S 125D]IL-4 8.7 ::!:0.9 4.9:!:3.2 1.7::!: 0.2 1 ±0.6 
[Y124D]IL-4 26 :!: 0.0-0.1 19 
Table 4. lnhibitory constants (K1) of IL-4 variants during IL-4-
induced CD23 expression in B-cells. The K; values were calculated 
from the IC50 values (Table 2) measured during dose-dependent inhi-
bition of CD23 induction in the presence of 67 pM IL-4. The EC50 
value of IL-4 for induction of CD23-positive B-cells was 1 pM and 
the EC50 value for the mean CD23 content was 6 pM. The K; values 
represent mean values :!: the Standard deviation. 
Protein 
[R121D, Y124D)IL-4 
[R121D,S125D]IL-4 
[Y124D,S125D]IL-4 
[R121D,Y124D,S125D]IL-4 
[Y124D]IL-4 
Inhibitory constants K; for 
IL-4-dependent induction of 
-- -·- -------
CD23-positi ve 
B-cells 
pM 
180::!: 1.0 
98:!: 13 
210::!: 22 
120:!: 13 
71::!: 11 
mean CD23 
content 
280 ::!:25 
190::!: 11 
320±44 
180::!: 12 
110::!:24 
Y124D]IL-4 inhibits IL-13-dependent CD23 induction to 
background Ievels (Fig. 3). The Ki values were calculated to 
be 130-160 pM. This is in the range of Kj values measured 
for the IL-4-dependent response aJthough the values are 
somewhat lower. 
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Fig.J. Inhibition of IL·13-dependent or IL-4-dependent CD23 
expression in B-cells by variant [Rl21D,Y124D]IL-4. Human B-
cells purified from spleen were incubated with 67 pM IL-4 (e, 0) 
or 800 pM IL-13 (A, 6) plus the indicated concentration of variant 
[R121D,Y124D]IL-4. After 18 h, the number of CD23-positive B-
cells (e, A) and the mean CD23 content of B-cells (0, 6) were 
measured by flow cytometry. For evaluation see Table 5. 
Monoclonal antibody X2/45 directed against IL-4Rex 
inhibits both IL·4·induced and IL-13·induced 
CD23 expression in B-cells 
The monoclonal antibody (mAb) X2/45 was prepared by 
immunizing mice with a recombinant extracel1ular domain 
Table 5. Inhibition by IL-4 variant [R121D,Y124D]IL-4 of IL-13-dependent or IL-4-dependent expression of CD23 in human ß. 
cells. In the inhibition assays, the concentration of IL-13 was 800 pM and the concentration of IL-4 was 67 pM. The K; values were 
calculated from the concentration of [R121D,Y124D]IL-4 causing half-maximal inhibition (IC50) oftheB-eeil responses; K; = IC5 ot'{1+ 
[IL]/EC50). The EC50 values represent mean values :!: the standard deviations. MFI designates the mean fluorescence intensity during CD23 
FACS analysis. 
Protein CD23-positive B-cells Mean CD23 content 
ECso Rmax Kj ECso Rmax K 
pM % pM pM MFI pM 
IL-4 3::!: 0.1 54(= 100) 13 ::!:0.8 361 (= 100) 
IL-13 60::!:5 41 (64) 152 ::!:9 110 (30.5) 
[R121D,Y124D]IL-4 plus IL-4 260 140 
[R121D,Y124D]IL-4 plus IL-13 130 150 
10-1 10° 101 1 ()2 
mAb X2145 (nM) 
Fig.4. Inhibition by mAb X2/45 of IL~13~dependent or IL-4-
dependent CD23 expression in human B-cells. Purified B-cells 
were incubated with 67 pM IL-4 (e, 0) or 800 pM IL-13 (A, 6.) 
plus increasing concentrations of mAb X2/45. After 18 h, CD23-
positive cells (e, A) and mean CD23 content (0, 6.) were deter-
mined by fluorescence-activated cell sorting. A quantitative evalua-
tion of the data is provided in Table 6 (experiment 2). 
Table 6. Inhibition by mAb X2/45 of IL-4-dependent or IL~ 13 
dependent expression of CD23 in B~cells. The Ki values were cal-
culated from the IC50 value in the presence of 67 pM IL-4 or 800 
pM IL-13. The respective EC50 values were taken from Table 5. 
Protein mAb X2/45 inhibition of induction of 
CD23-positive B-cells mean CD 23 content 
experiment 1 experiment 2 experiment 1 experiment 2 
nM 
IL-4 4.3 
IL-13 8.8 
3.1 
3.6 
7.7 
11.4 
6.4 
3.1 
IL-4R..x of the IL-4 receptor a subunit (Kruse et al., 1993). 
X2/45 interferes with IL-4 binding and inhibits IL-4-induced 
T-cell proliferation with a Ki value of 20 nM. X2/45 specifi-
cally recognizes the IL-4 receptor a chain on the cell surface 
as was shown by flow cytometry (Reusch, P., unpublished 
results). 
As demonstrated in Fig. 4 and Table 6, mAb X2/45 inhib-
its IL-13-dependent CD23 induction in B-cells as efficiently 
as the IL-4-dependent response. The activity of both interleu-
kins can be inhibited to background Ievels and the Ki values 
are in the same range (3-12 nM). An isotype matched con-
trol mAb (anti-CD4) had no effect at comparable concentra-
tions. This indicates that IL-4R..x is necessary for IL-4 and 
for IL-13 activity. 
Inhibition of IL-4-induced and IL-13-induced 
proliferation of the TFl cell line by mAb X2/45 
and IL-4 variant [R121D,Y124D]IL-4 
The premyeloid erythroleukemia cell line TF-1 prolifer-
ates in response to both human IL-4 and human IL-13. Both 
responses are inhibited by signalling site variant [Y124D]IL-
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4 (Zurawski et al., 1993). The experiments described in Table 
7 extend these findings employing variant [R121D, 
Y124D]IL-4. ln addition, the inhibitory action of anti IL-
4Rex mAb X2/45 on both IL-4 and IL-13 activity is demon-
strated. In TF-1 cells, the maximal response for IL-13 (Rmax) 
was only 20-25% of the Rmax produced by IL-4. The EC50 
value of IL-13 was 4-8-fold higher than the EC50 value of 
IL-4. The activity of both cytokines could be inhibited by 
variant [R121D,Y124D]IL-4 with a Ki value of 40-80 pM. 
The very high-affinity binding site on TF-1 cells for human 
IL-4 (Kd less than 10 pM, see Zurawski et al., 1993) could 
not be detected during competitive radioligand binding. A Kd 
of 100 to 150 pM was determined for IL-4 binding in the 
presence of 125 pM 1251-labeled IL-4 as weil as in the pres-
ence of 2.5 pM 1251-labeled IL-4 (data not shown). 
DISCUSSION 
Extending our previous studies on IL-4 variants, the pre-
sent results demonstrate that it is feasible to rationalJy design 
a second generation of human IL-4 antagonists/partial ago-
nists displaying extremely low efficacy. Furthennore, these 
data together with the data on the inhibitory activity of anti 
IL-4Re;\ monoclonal antibodies yields information on the 
functional interaction of IL-4 with its receptor subunits and 
on the essential role of the established IL-4 receptor a subunit 
during both IL-4-dependent and IL-13-dependent responses 
in T-cells and B-cells. 
The loss of signaHing activity (efficacy) in multiple IL-4 
variants appears to be caused by the defective signalling site 
comprising the juxtaposed amino acid side chains at posi-
tions 121, 124 and 125 of helix D. [Allosteric effects due to 
the amino acid replacement arenot detected by high-resolu-
tion three-dimensional NMR spectroscopy (Müller et al., 
1994; Müller, unpublished results) and the binding affinity 
to IL-4R..x remains largely unaltered]. The signalling activity 
of this site depends on a hydrophobic patch provided by 
Tyr124 ( or another I arge hydrophobic side chain) and is 
weakened specifically if the negatively charged side chain of 
aspartic acid is present (Demchuk et al., 1994). The occur-
rence at positions 121 and 125 of small, large hydrophobic, 
polar, or glutamyl residues introduced at this position has no 
or only small effects (Kruse N. and Sebald, W., unpublished 
results). A positional effect of the aspartic acid side chain is 
suggested by the observation that IL-4 variants [Y124N]IL-
4 and [Y124D]IL-4 show an at least 20-fold difference in 
efficacy, whereas the difference between wild-type IL-4 and 
[R121D]IL-4 or [S125D]IL-4 is only 2-5-fold. The partial 
agonist activities for B-eeil CD23 induction indicates that 
variants [Y124D, S125D]IL-4 and [R121D,Y124D,S125D]IL-
4 are slightly more active than [R121D,Y124D]IL-4. Ac-
cordingly, an aspartic acid residue at position 121 is more 
inhibitory than an aspartic acid residue at position 125. But 
these small differences should not be overemphasized. 
In the double variants, the effect of the individual amino 
acid replacements may be more than additive. The loss of 
potency in variant [R121D,S125D]IL-4 is more than 100-
fold. The additive loss would have been approximately ten-
fold. In variant [R121D,Y124D]IL-4, no agonist activity 
could be measured. This indicates a more than 2000-fold re-
duced potency compared to IL-4 (considering the back-
ground and the sensitivity oftheB-eeil assay). This is again 
slightly above the value expected from the added 
effects in [R121D]IL-4 (approximately three-fold) and 
[Y124D]IL-4 (greater than 100 fold). 
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Table 7. Inhibition of IL-4-dependent or IL-13-dependent TFl cell proliferation by variant [R121D,Y124D]IL-4 or mAb X2/45. Rm•• 
values are given relative to the maximal IL-4 response (30800 cpm incorporated 3H-thyrnidine radioactivity). The inhibitory constants K; 
were calculated from the concentration of [R121D,Y124D]IL-4 or mAb X2/45 causing half-maximal inhibition (IC50); K; = IC5o/(1 +[IL]/ 
EC50). The concentration in the inhibition assays was 200 pM for IL-4 and 800 pM for IL-13. 
Protein 
IL-4 
IL-13 
IL-4 plus [R121D,Y124D]IL-4 
IL-4 plus X2/45 
IL-13 plus [R121D,Y124D]IL-4 
IL-13 plus X2/45 
TF-1 cell proliferation 
experiment 1 
ECso 
pM 
14 
250 
% 
100 
20 
It has been discussed (Rigley et al., 1991) that B-cells 
contain two different IL-4 receptors as one possibility to ex-
plain the different sensitivities to IL-4 and anti-CD19 mAb 
and the different intracellular signalling requirement for in-
duction of surface IgM and mean CD23 content in human 
tonsillar B-cells. The present study did not analyse IL-4-de-
pendent surface IgM expression in B-cells. The inhibition by 
anti IL-4Rex mAb X2/45 of both the very sensitive induction 
of CD23-positive B-cells (EC50 1-3 pM in these experi-
ments) and the mean CD23 content in B-cells (EC50 3-13 
pM) indicate however, that the IL-4 receptor a subunit is 
involved in both of these B-cell responses. Thus, it is a dis-
tinct possibility that these graded sensitivities of IL-4 re-
sponses result from different post-receptor signalling steps. 
In previous sturlies it has been demonstrated (Aversa et 
al., 1993~ Zurawski et al., 1993) that IL-13 partially inhibits 
IL-4 binding to TF-1 cells and that IL-13-dependent re-
sponses are inhibited by variant [Y124D]IL-4. These results 
showed that the IL-4 and IL-13 receptor systems are complex 
and share a common component. The present data indicate 
that this common component comprises at least the IL-4 re-
ceptor a subunit, since both anti IL-4Rex mAb X2/45 and the 
new IL-4 antagonist [R121D,Y124D]IL-4 (similar but more 
efficient than [Y124D]IL-4) inhibit B-eeil CD23 induction 
by both IL-4 and IL-13. 
It is a reasonable working hypothesis that the signalling 
site of human IL-4, i.e. the amino acid side chains at posi-
tions 121, 124 and 125 interact with the common y chain, 
which has been identified first in the IL-2 receptor system 
and which has been later established to be also a constitutent 
of the IL-4 and IL-7 receptor systems (Kondo et al., 1993; 
Russell et al., 1993; Kondo et al., 1994). Actually, conspicu-
ous similarities can be detected if the corresponding surface 
areas of human IL-4 and IL-2 are compared (Müller, T., un-
published results). It is unknown at this time whether or not 
the common y chain also functions in the IL-13 receptor sys-
tem. The C-terminus of human and murine IL-13 exhibits 
· some similarities to the signalling site of IL-4, although one 
published alignment (Zurawski et al., 1993) postulates the 
insertion of a glycine residue at the corresponding IL-13 se-
quence. It is tempting to speculate that the IL-13 receptor 
system uses both the IL-4 receptor a subunit and the common 
y chain and that IL-13 specificity is determined by an addi-
tional third chain similar to the ciliary-neutrophic-factor re-
ceptor system (Davis et al., 1993; Kishimoto et al., 1994 ). 
Accordingly, the nonproductive complex postulated to be 
nM 
2.6 
1.6 
experirnent 2 
ECso 
pM 
25 
170 
Rmax K; 
% pM 
1.00 
21 
76 
36 
formed by the human IL-4 antagonists (Zurawski et al., 
1993) might be a 1:1 complex between the IL-4 receptor a 
subunit and the IL-4 antagonist, which cannot associate fur-
ther due to the defective signaHing site with the common y 
chain to form the functional IL-4 receptor or with the com-
mon y chain plus the IL-13-binding protein to form the func-
tional IL-13 receptor. 
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